Biography
Aras N. Mattis, M.D., Ph.D., is a board-certified anatomic pathologist and clinical fellow in the Willenbring Lab. Dr. Mattis trained at the University of Illinois at Urbana-Champaign, earning both his doctorates, Biochemistry and Medicine, there in 2007. He continued his clinical training in Pathology at the University of California San Francisco completing residency in Anatomic Pathology with subsequent fellowship training in Surgical Pathology and Liver and gastrointestinal pathology under his clinical mentor, Dr. Linda Ferrell. Since 2010, he has worked in the Willenbring Lab, investigating the basic mechanisms of liver development and disease in the with a specific focus on liver metabolism and fatty liver disease as well as micro-RNA regulation of liver metabolism.
Education
Institution | Degree | Dept or School | End Date |
---|---|---|---|
University of Illinois Urbana-Champaign | PhD | Biochemistry | 2007 |
University of Illinois Urbana-Champaign | MD | Medicine | 2007 |
University of California Berkeley | BA | Molecular and Cell Biology - Genetics | 1998 |
Board Certifications
American Board of Pathology, Anatomic Pathology
Collaboration Interests
I am interested in:
- academic collaboration
- academic senate committee service
- companies and entrepreneurs
- multicenter clinical research
- press
- prospective donors
Clinical Expertise
Liver and Gastrointestinal Pathology
Program Affiliations
UCSF Department of Pathology
California Institute for Regenerative Medicine
In the News
Grants and Funding
- Establishing patient-derived iPSCs as a platform for discovery research in NAFLD | NIDDK | 2023-06-01 - 2028-05-30 | Role: MPI
- Modeling and Characterization of NAFLD Phenotypes in a Severely Affected Family | NIH/NIDDK | 2024-02-01 - 2027-11-30 | Role: PI
- Genetic Regulation of Nonalcoholic Fatty Liver Disease | NIH | 2021-06-08 - 2025-03-31 | Role: MPI
- Regulation of Lipid Metabolism by miR-29a within Hepatocytes | NIH | 2013-09-01 - 2019-07-31 | Role: Principal Investigator
Research Narrative
Dr. Mattis' postdoctoral work includes the use of translational human biopsy material as well as patient-derived induced pluripotent stem cell reprogramming to hepatocytes. As a long-term goal, this work aims to develop a humanized liver mouse model of fatty liver disease. Aras is supported by the UCSF CIRM clinical fellow training grant and continues to work closely with the UCSF Department of Pathology as a clinical researcher.
Research Interests
Liver diseases including metabolic, pediatric, fibrotic, idiopathic, stem cell derived
Hepatocytes for transplant and disease modeling, micro-RNA regulation of hepatocyte
Development and metabolism, liver and gastrointestinal tumors, site-specific recombination.
Publications
- Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data.| | PubMed
- DNA content abnormality frequently develops in the right/proximal colon in patients with primary sclerosing cholangitis and inflammatory bowel disease and is highly predictive of subsequent detection of dysplasia.| | PubMed
- Self-Assembled Matrigel-Free iPSC-Derived Liver Organoids Demonstrate Wide-Ranging Highly Differentiated Liver Functions.| | PubMed
- Fundic Gland Polyps Lack DNA Content Abnormality Characteristic of Other Adenomatous Precursor Lesions in the Gastrointestinal Tract.| | PubMed
- Transient expression of factor VIII and a chronic high-fat diet induces ER stress and late hepatocyte oncogenesis.| | PubMed
- Targeting acid ceramidase ameliorates fibrosis in mouse models of non-alcoholic steatohepatitis.| | PubMed
- Undifferentiated Induced Pluripotent Stem Cells as a Genetic Model for Nonalcoholic Fatty Liver Disease.| | PubMed
- Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review.| | PubMed
- Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A.| | PubMed
- Nonampullary Duodenal Adenomas in Familial Adenomatous Polyposis and Sporadic Patients Lack the DNA Content Abnormality That Is Characteristic of the Adenoma-Carcinoma Sequence Involved in the Development of Other Gastrointestinal Malignancies.| | PubMed